

United Arab Emirates


Treatment at diagnosis by country

Global enrolment of Prospective patients


Region	n	%
Europe	29167	56
Asia	14988	28.8
North America	1618	3.1
Latin America	4247	8.2
Rest of World	2061	4
Total	52081	100




Treatment at diagnosis by country



Treatment at diagnosis by region



Treatment at diagnosis by cohort



Baseline characteristics

		United Arab Emirates N=(397)	World N=(52081)
Sex	Female, n (%)	137 (34.5)	23015 (44.2)
Age at Diagnosis (Years)	mean (sd)	62.4 (13.9)	69.7 (11.5)
Age Group	<65, n (%)	217 (54.7)	15716 (30.2)
	65-74, n (%)	115 (29.0)	16956 (32.6)
	>=75, n (%)	65 (16.4)	19409 (37.3)
BMI (kg/m ²)	mean (sd)	30.0 (6.6)	27.8 (5.7)
Pulse (bpm)	mean (sd)	106.9 (29.2)	90.4 (26.7)
Systolic BP (mm Hg)	mean (sd)	129.7 (21.7)	133.5 (19.8)
Diastolic BP (mm Hg)	mean (sd)	76.6 (16.1)	79.7 (12.9)
Congestive heart failure	n (%)	74 (18.6)	10405 (20.0)
Coronary artery disease	n (%)	133 (33.5)	11251 (21.6)
Acute coronary syndrome	n (%)	81 (20.4)	4914 (9.5)
Carotid Occlusive Disease	n (%)	5 (1.3)	1546 (3.0)
Cirrhosis	n (%)	2 (0.5)	296 (0.6)

Baseline characteristics

		United Arab Emirates N=(397)	World N=(52081)
Diabetes	n (%)	180 (45.3)	11550 (22.2)
History of Bleeding	n (%)	11 (2.8)	1320 (2.5)
Hypercholesterolaemia	n (%)	221 (56.1)	20975 (41.6)
PE or DVT	n (%)	2 (0.5)	1356 (2.6)
Stroke/TIA	n (%)	32 (8.1)	5961 (11.4)
Treatment Sector	In the private sector, n (%)	52 (13.3)	12547 (28.5)
	In the public sector, n (%)	339 (86.7)	31431 (71.5)

Baseline characteristics

		United Arab Emirates N=(397)	World N=(52081)
CHADS2 Score	mean (sd)	1.8 (1.1)	1.9 (1.1)
CHA2DS2-VASc Score	mean (sd)	2.9 (1.7)	3.2 (1.6)
HAS BLED Score	mean (sd)	1.4 (1.0)	1.4 (0.9)

Baseline characteristics

		United Arab Emirates N=(397)	World N=(52081)
Systemic Embolization	n (%)	1 (0.3)	336 (0.6)
Type of AF Diagnosed	New, n (%)	321 (80.9)	23366 (44.9)
	Paroxysmal, n (%)	62 (15.6)	14313 (27.5)
	Permanent, n (%)	3 (0.8)	6639 (12.7)
	Persistent, n (%)	11 (2.8)	7761 (14.9)
Care Setting Speciality at Diagnosis	Cardiology, n (%)	357 (89.9)	34219 (65.7)
	Geriatrics, n (%)	0 (0.0)	202 (0.4)
	Internal Medicine, n (%)	33 (8.3)	9372 (18.0)
	Neurology, n (%)	4 (1.0)	876 (1.7)
	Primary Care/General Practice, n (%)	3 (0.8)	7410 (14.2)


Main reason anticoagulant not used for patients with $\text{CHA}_2\text{DS}_2\text{-VASc} \geq 2$.

Cohort 1&2	
	World (N=4137) n %
Patients with $\text{CHA}_2\text{DS}_2\text{-VASc} \geq 2$ and no AC treatment at diagnosis	
Alcohol abuse	20 (0.5)
Already taking anti-platelet drugs for other medical condition	228 (5.5)
Patient refusal	336 (8.1)
Previous bleeding event	63 (1.5)
Taking medication contraindicated or cautioned for use with VKA or AC	19 (0.5)
Other	505 (12.2)
Unknown	889 (21.5)
Physician's choice	2077 (50.2)
Physician's choice - Bleeding risk	263 (6.4)
Physician's choice - Concern over patient compliance	182 (4.4)
Physician's choice - Guideline recommendation	105 (2.5)
Physician's choice - Fall risk	197 (4.8)
Physician's choice - Low risk of stroke	326 (7.9)
Physician's choice - Other	1004 (24.3)
Total	4137 (100.0)


Main reason anticoagulant not used for patients with $CHA_2DS_2-VASc \geq 2$.

	Cohort 3&4&5	
	United Arab Emirates (N=70) n %	World (N=6117) n %
Patients with $CHA_2DS_2-VASc \geq 2$ and no AC treatment at diagnosis		
Alcohol abuse		32 (0.5)
Already taking anti-platelet drugs for other medical condition	10 (14.3)	422 (6.9)
Patient refusal	7 (10.0)	645 (10.5)
Previous bleeding event	5 (7.1)	151 (2.5)
Taking medication contraindicated or cautioned for use with VKA or AC		63 (1.0)
Other	16 (22.9)	1326 (21.7)
Unknown	3 (4.3)	1597 (26.1)
Physician's choice	29 (41.4)	1881 (30.8)
Physician's choice - Bleeding risk	13 (18.6)	611 (10.0)
Physician's choice - Concern over patient compliance	4 (5.7)	248 (4.1)
Physician's choice - Guideline recommendation	6 (8.6)	189 (3.1)
Physician's choice - Fall risk		205 (3.4)
Physician's choice - Low risk of stroke	6 (8.6)	628 (10.3)
Total	70 (100.0)	6117 (100.0)


Stroke risk profile: CHADS₂



Stroke risk profile: CHA₂DS₂ VASc



Stroke risk profile: HAS BLED




Treatment at diagnosis by CHA₂DS₂-VASc score - United Arab Emirates

CHA ₂ DS ₂ -VASc		AP	VKA+AP	FXa+AP	None	DTI+AP	Unknown	Total
		n	n	n	n	n	n	n
United Arab Emirates	Unknown	3	0	0	0	0	0	3
	0	5	3	2	13	0	0	23
	1	30	7	15	9	7	0	68
	2	22	11	14	7	21	0	75
	3	26	22	10	7	22	0	87
	4	20	16	10	4	19	0	69
	5	13	8	6	5	6	2	40
	6-9	12	6	3	0	11	0	32


Treatment at diagnosis by CHA₂DS₂-VASc score - World

CHA ₂ DS ₂ -VASc		VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total
		n	n	n	n	n	n	n
World	Unknown	461	227	62	286	330	14	1380
	0	325	221	111	302	443	16	1418
	1	1830	1097	479	1545	1196	66	6213
	2	3835	1960	806	2154	1261	125	10141
	3	4969	2625	817	2345	1275	164	12195
	4	4711	2352	772	2043	1028	168	11074
	5	2458	1169	375	1224	449	98	5773
	6-9	1616	831	234	872	261	73	3887

Treatment at diagnosis



Treatment at diagnosis




Treatment at diagnosis by HAS BLED score - United Arab Emirates

HASBLED		VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total	
		n	n	n	n	n	n	N	n
United Arab Emirates	Unknown	12	2	16	17	2	1	50	50
	0	9	13	16	0	26	0	64	64
	1	27	28	26	48	7	0	136	136
	2	16	11	18	43	8	0	96	96
	3	9	5	7	17	2	1	41	41
	4-9	0	1	3	6	0	0	10	10


Treatment at diagnosis by HAS BLED score - World

HASBLED		VKA±AP	FXa±AP	DTI±AP	AP	None	Unknown	Total
		n	n	n	n	n	n	n
World	Unknown	5750	2456	843	3271	2060	147	14527
	0	2144	1242	611	0	1394	96	5487
	1	6650	3866	1303	2302	1779	254	16154
	2	4165	2225	689	3689	763	163	11694
	3	1258	599	191	1250	219	53	3570
	4-9	238	94	19	259	28	11	649

Treatment at diagnosis



Treatment at diagnosis



INR values and time in therapeutic range

Variable	Statistics	United Arab Emirates (N = 73) n %	World (N = 20205) n %
INR value, n(%)	n (missing)	436 (32)	157134 (8319)
	<2	116 (26.6)	50514 (32.1)
	2-3	236 (54.1)	81056 (51.6)
	>3	84 (19.3)	25564 (16.3)
INR value	n (missing)	436 (32)	157134 (8319)
	Mean (SD)	2.5 (1.0)	2.4 (0.9)
	Median (IQR)	2.3 (1.9 to 2.8)	2.3 (1.8 to 2.8)
	Min to Max	1.0 to 11.4	0.8 to 20.0
TTR, n(%)	n (missing)	40 (33)	11485 (8720)
	<65	17 (42.5)	6734 (58.6)
	>=65	23 (57.5)	4751 (41.4)
TTR	n (missing)	40 (33)	11485 (8720)
	Mean (SD)	65.4 (23.9)	55.2 (27.3)
	Median (IQR)	68.8 (53.2 to 81.3)	59.0 (37.0 to 76.1)
	Min to Max	0.0 to 100.0	0.0 to 100.0

Event rates during the first year of follow-up (rates per 100 person-years)

	United Arab Emirates		World	
	Events	Rate (95% CI)	Events	Rate (95% CI)
Death	25	6.75 (4.56 to 9.99)	2103	4.38 (4.20 to 4.57)
Cardiovascular Death	7	1.89 (0.90 to 3.97)	789	1.64 (1.53 to 1.76)
Non-cardiovascular death	12	3.24 (1.84 to 5.71)	771	1.61 (1.50 to 1.72)
Undetermined Cause	6	1.62 (0.73 to 3.61)	543	1.13 (1.04 to 1.23)
Stroke/SE	2	0.54 (0.14 to 2.16)	650	1.36 (1.26 to 1.47)
Major Bleeding	3	0.81 (0.26 to 2.52)	407	0.85 (0.77 to 0.94)
Acute coronary syndrome	3	0.81 (0.26 to 2.51)	378	0.79 (0.71 to 0.87)
Congestive hearth failure	1	0.27 (0.04 to 1.91)	1052	2.22 (2.09 to 2.35)

Cause of death during the first year of follow-up

	United Arab Emirates		World	
	n	%	n	%
Cardiovascular causes				
Congestive heart failure	1	14.3	262	33.2
Sudden or unwitnessed death	0		127	16.1
Myocardial infarction	1	14.3	89	11.3
Non-haemorrhagic stroke (Ischemic Stroke)	0		86	10.9
Non Cardiovascular causes				
Malignancy	0		233	30.2
Respiratory failure	1	8.3	142	18.4
Infection	6	50.0	81	10.5
Sepsis	3	25.0	74	9.6

Type of stroke during the first year of follow-up

	United Arab Emirates		World	
	n	%	n	%
Stroke (not including systemic embolism)	2	0.50	585	1.12
Primary Ischemic	2	0.50	406	0.78
of which secondary hemorrhagic ischemic			22	0.04
Primary intracerebral hemorrhage			71	0.14
Intracerebral			44	0.08
Intraventricular			9	0.02
Subarachnoid			13	0.02
Undetermined			108	0.21

Severity of bleeding during the first year of follow-up

Outcome	United Arab Emirates		World	
	n	%	n	%
Major Bleed	3	0.01	407	0.78
Non-Major Clinically Relevant	3	0.01	645	1.24
Minor	2	0.00	1167	2.24
Unknown			136	0.26